ArticleBioanalysis2025
Metabolic alterations in the serum of patients with acute ischemic stroke.
Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Untargeted Metabolomic Signature of Mice with Ischemic Stroke.Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIschemic stroke (IS) occurs when a clot obstructs cerebral blood flow, leading to potentially irreversible damage. Metabolites, as the end products of cellular metabolism, can reflect pathological changes in the body. This study aimed to characterize serum metabolic alterations associated with acute ischemic stroke.
methodParticipants were divided into discovery and validation sets, each comprising healthy controls and IS patients. In the discovery set, untargeted serum metabolomic profiling was performed using liquid chromatography - tandem mass spectrometry. Metabolites showing significant intergroup differences were selected as biomarker candidates and quantitatively validated in the independent set. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis.
resultsThree metabolites - cytidine, decanoyl-L-carnitine, and 2-hydroxyestradiol - were identified as significantly altered in IS patients. Cytidine and 2-hydroxyestradiol demonstrated excellent diagnostic performance (AUCs of 0.968 and 0.929, respectively), while decanoyl-L-carnitine showed good performance (AUC = 0.808).
conclusionThe three metabolites exhibit significant alterations in acute ischemic stroke patients and provide insight into disease-associated metabolic changes. Their validation lays the groundwork for future exploratory studies investigating potential biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.